Clinical trial Recruiting at 10 sites Phase 1 Interventional Ages 50 to 75

V132 vaccine safety in healthy older adults

Official title: A Phase 1, Randomized, Double-Blind, Comparator-Controlled Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of V132 in Healthy Older Participants

Run by Merck Sharp & Dohme LLC · NCT07712575 · Data updated 2026-11-12

This study tests the safety and immune response of V132 formulations in healthy older adults to see if the vaccine is safe and prompts an immune reaction.

More Healthy Aging trials

Quick facts

PhasePhase 1
Study typeInterventional
Ages50 Years to 75 Years
SexAll
Enrollment280 (estimated)
SponsorMerck Sharp & Dohme LLC
Industry-sponsored
Locations10 sites (Anaheim, California and 9 other locations)
StatusRecruiting
StartedAugust 12, 2026
Main results expectedMay 5, 2028
Study endsMay 5, 2028
Registry record updatedOctober 20, 2026
Trial IDNCT07712575 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Healthy adults aged older than 60 with BMI between 18.0 and 35.0 kg/m^2 who have no recent history of invasive or culture-positive pneumococcal disease and no prior pneumococcal vaccines within specified windows.

Probably not a fit

Individuals with recent pneumococcal disease, recent or any prior pneumococcal conjugate vaccination, or other significant health issues may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 trial evaluates multiple formulations of the V132 vaccine in healthy adults aged older than 60. Participants receive one of several V132 formulations or comparator vaccines to monitor safety and immune responses. The study excludes individuals with recent pneumococcal disease or prior pneumococcal vaccines within specified timeframes. Sites are located in California and Florida, enrolling participants in a controlled clinical setting with routine follow-up visits. Data will inform whether V132 can safely provoke an immune response in this population.

Why it matters

Potential benefit: If successful, participants may gain information about the vaccine's safety and potential immune benefits for older adults.

How similar studies have gone: Past pneumococcal vaccine studies have shown acceptable safety and immunogenicity in similar populations, though this specific V132 formulation set is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

The key inclusion criteria include but are not limited to the following:

* Is in good health
* Has body mass index (BMI) within 18.0 to 35.0 kg/m\^2 (inclusive)

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

* Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination
* Has received a pneumococcal polysaccharide vaccine in the previous 10 years, has received any pneumococcal conjugate vaccine at any time prior to this study

Where it's running

  • Anaheim Clinical Trials ( Site 0006)
    Anaheim, California, United States
    Recruiting
  • Velocity Clinical Research, Hallandale Beach ( Site 0003)
    Hallandale, Florida, United States
    Recruiting
  • Research Centers of America ( Hollywood ) ( Site 0009)
    Hollywood, Florida, United States
    Recruiting
  • QPS-MRA, LLC-Early Phase ( Site 0001)
    South Miami, Florida, United States
    Recruiting
  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0002)
    Springfield, Missouri, United States
    Recruiting
  • Velocity Clinical Research Lincoln ( Site 0007)
    Lincoln, Nebraska, United States
    Recruiting
Show 4 more locations
  • Velocity Clinical Research, Omaha ( Site 0008)
    Omaha, Nebraska, United States
    Recruiting
  • Remington-Davis, Inc. ( Site 0005)
    Columbus, Ohio, United States
    Recruiting
  • Velocity Clinical Research, Providence ( Site 0010)
    East Greenwich, Rhode Island, United States
    Recruiting
  • University of Texas Medical Branch ( Site 0004)
    League City, Texas, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.